DOD Lung Cancer, Patient-Centered Outcomes and Survivorship Award
ID: 353174Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353174
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Lung Cancer, Patient-Centered Outcomes and Survivorship Award, aimed at funding innovative research to improve health outcomes for individuals affected by lung cancer. This grant supports high-risk, high-reward studies that focus on behavioral health, survivorship, and the overall patient experience, particularly for Service Members, Veterans, and the general public. With an estimated total program funding of $2,080,000 and the expectation of awarding two grants, the application process includes a pre-application due by July 17, 2024, and a full application by August 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524LCRPPCOSA-GG.pdf
    The DOD FY24 Lung Cancer Patient-Centered Outcomes and Survivorship Award program announcement outlines funding opportunities for innovative research related to lung cancer, aimed specifically at improving patient outcomes for Service Members, Veterans, and the general public. With an appropriation of $25 million for FY24, the program encourages interdisciplinary studies that address critical areas such as health outcomes, survivorship, and disparities in lung cancer care. Key submission deadlines include a pre-application due on July 17, 2024, and a full application by August 7, 2024. The application process consists of a two-step submission via eBRAP and Grants.gov, includes specific eligibility criteria, and requires comprehensive project proposals focusing on evidence-based approaches. The awarded projects must demonstrate substantial relevance to military health and adhere to detailed review criteria assessing research strategy, impact, and statistical methodologies. A strong emphasis is placed on involving patient advocates and ensuring studies are designed with military populations in mind, reflecting the program’s commitment to addressing lung cancer's pervasive impact on both military families and broader health disparities.
    Similar Opportunities
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    Notice of Intent to Publish a Funding Opportunity Announcement for Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) initiative, specifically targeting Tobacco Use Treatment for Cancer Survivors. This initiative aims to fund up to three research projects that will develop and test strategies to enhance the delivery and sustainability of tobacco use treatment services for cancer survivors, utilizing the UG3/UH3 Exploratory/Developmental Cooperative Agreement activity code, which requires clinical trials. The total estimated funding for this opportunity is $2.4 million, with applications expected to be due in late Fall 2024 and awards anticipated by July 1, 2025. Interested applicants are encouraged to prepare by reviewing related materials and attending a pre-application webinar, details of which will be announced following the NOFO publication.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
    Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), is offering a funding opportunity titled "Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers." This initiative aims to support research proposals that develop and test multi-level interventions to improve the quality of transitional care and enhance engagement for over 500,000 U.S. cancer survivors transitioning from pediatric to adult healthcare systems. The program emphasizes addressing health disparities and requires applications to demonstrate scalability and sustainability of proposed interventions, fostering effective communication between patients and providers. The total funding available is approximately $10 million, with a maximum annual budget cap of $499,000 per project over a five-year period. Interested applicants must submit their proposals by October 18, 2025, with projects expected to commence in March 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-019.html.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity aimed at improving care and outcomes for cancer survivors from sexual and gender minority (SGM) populations. This initiative seeks proposals for observational and interventional studies that assess barriers to quality cancer treatment and follow-up care for SGM individuals, utilizing interoperable sexual orientation and gender identity (SOGI) data collection methods. The funding is crucial for addressing healthcare disparities faced by SGM cancer survivors and aims to foster culturally sensitive care and effective interventions. Applications are due starting January 5, 2024, with funding available for up to five years, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations," aimed at addressing the unique challenges faced by SGM cancer survivors in accessing quality treatment and follow-up care. This funding initiative seeks proposals for observational and interventional studies that utilize interoperable sexual orientation and gender identity (SOGI) data collection methods to identify barriers and enhance care for SGM individuals with cancer. The initiative emphasizes the importance of stakeholder engagement and collaboration with SGM communities to mitigate health disparities and improve health equity within cancer care. Interested applicants can find more information and application guidelines at the NIH grants website, with proposals due by January 7, 2027. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.